HelicoCARE direct

HelicoCARE direct is a medical diagnostic product designed to detect antibodies against Helicobacter pylori, the bacterium associated with conditions including peptic ulcer disease. The test was introduced worldwide in 2006 and is manufactured by CARE diagnostica. It uses an immunochromatographic format and accepts whole-blood samples, distinguishing it from laboratory approaches that require more specialized specimen collection or equipment. The product’s principal use is screening. By identifying an antibody response to H. pylori in a blood sample, HelicoCARE direct can support the initial assessment of individuals or populations in which infection is suspected. The available reference material specifically describes the test as suitable for screening large populations for peptic ulcer disease. As an antibody-based assay, its result indicates an immune response to the bacterium; the available material does not establish the product’s intended role in confirming active infection, monitoring eradication, or replacing clinical evaluation. The brand’s value proposition is centered on accessibility and operational simplicity. Whole-blood testing and immunochromatographic technology are commonly associated with rapid, point-of-care or near-patient workflows, although the available references do not provide a stated turnaround time, performance figures, regulatory approvals, packaging configuration, distribution model, or detailed instructions for use. No reliable information is available here about the manufacturer’s corporate structure, headquarters, current commercial status, pricing, or specific markets beyond the product’s reported worldwide introduction. HelicoCARE direct should therefore be understood as a narrowly defined in-vitro diagnostic product rather than a broad healthcare company or a general Helicobacter pylori treatment brand. Its documented history is limited to its 2006 worldwide introduction and its manufacture by CARE diagnostica. Additional information would be needed to describe later product generations, clinical validation, regulatory milestones, sales performance, current availability, or the brand’s present position in the diagnostic market.

HelicoCARE direct is a diagnostic test associated with CARE diagnostica. The product was introduced worldwide in 2006 as a whole-blood antibody test for Helicobacter pylori. Its underlying method is immunochromatography: the test is designed to identify antibodies directed against H. pylori in a blood specimen. The product is documented as a screening tool, particularly for use in larger populations being assessed in relation to peptic ulcer disease. Its whole-blood format suggests a workflow intended to simplify specimen handling compared with laboratory methods requiring more extensive sample preparation, although the available reference material does not state the exact operating procedure, result time, sensitivity, specificity, or required equipment. The available record does not identify a founder, launch campaign, regulatory jurisdiction, headquarters, commercial successor, or later versions of the product. It also does not establish whether the brand remains actively marketed. No financial, ownership, executive, litigation, recall, or controversy information is documented in the supplied materials. Accordingly, the known history of HelicoCARE direct is limited to its product category, manufacturer, testing method, intended screening application, and reported worldwide introduction in 2006.

1. 2006Worldwide introduction

   HelicoCARE direct was introduced worldwide as an immunochromatographic whole-blood antibody test for Helicobacter pylori.

   Source

A screening-oriented immunochromatographic in-vitro diagnostic for detecting antibodies against Helicobacter pylori in whole-blood samples.

• HelicoCARE directIn-vitro diagnostic test2006

  HelicoCARE direct is an immunochromatographic assay manufactured by CARE diagnostica. It is designed to detect antibodies against Helicobacter pylori in whole-blood samples. The product is described as suitable for screening large populations in connection with peptic ulcer disease. Available references do not provide detailed analytical performance data, instructions for use, regulatory information, or current availability.

1. HelicoCARE direct